NCT02589405

Brief Summary

The aim of this study is to evaluate a complete acne regimen consisting of a medication (Benzaknen® 5% Gel), and 2 cosmetic products Dermotivin® Soft Liquid soap and Cetaphil® Dermacontrol Moisturizer SPF30 in patients with acne.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Aug 2015

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2015

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 23, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 28, 2015

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2016

Completed
3.1 years until next milestone

Results Posted

Study results publicly available

February 11, 2019

Completed
Last Updated

February 18, 2021

Status Verified

September 1, 2018

Enrollment Period

5 months

First QC Date

October 23, 2015

Results QC Date

August 25, 2017

Last Update Submit

February 16, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Participants Satisfied and Very Satisfied With Regimen

    Number of subjects satisfied and very satisfied with the three-part treatment regimen

    12 weeks

Study Arms (1)

Benzaknen treatment regimen

EXPERIMENTAL

Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)

Drug: Benzoyl PeroxideOther: Dermotivin® Soft Liquid cleanserOther: Cetaphil® Dermacontrol Moisturizer SPF30

Interventions

Benzaknen treatment regimen
Benzaknen treatment regimen
Benzaknen treatment regimen

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female subject of any ethnic background of 12 years or older.
  • Subject with mild or moderate facial acne vulgaris defined as an Investigator Global Assessment (IGA) score at 2 or 3 on a 0-4 scale.
  • Subject with any skin phototype according to T.B. Fitzpatrick skin phototype definitions.

You may not qualify if:

  • Subject with severe acne (IGA\>3) with nodules, cysts, scars or extra-facial lesions,
  • Female subject who is pregnant, lactating or planning a pregnancy during the study,
  • Subject susceptible to take a corticosteroid treatment during the study except inhaled or topic when needed to treat a condition outside the face,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

EGBERT Mi-Ran

Münster, 48159, Germany

Location

Related Publications (1)

  • Kim MR, Kerrouche N. Combination of benzoyl peroxide 5% gel with liquid cleanser and moisturizer SPF 30 in acne treatment results in high levels of subject satisfaction, good adherence and favorable tolerability. J Dermatolog Treat. 2018 Feb;29(1):49-54. doi: 10.1080/09546634.2017.1342758. Epub 2017 Jul 5.

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Benzoyl Peroxide

Condition Hierarchy (Ancestors)

Acneiform EruptionsSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

BenzoatesAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Results Point of Contact

Title
Stephanie Leclerc
Organization
Galderma R&D

Study Officials

  • Mi-Ran EGBERT, MD

    Proinnovera GmbH

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 23, 2015

First Posted

October 28, 2015

Study Start

August 1, 2015

Primary Completion

January 1, 2016

Study Completion

January 1, 2016

Last Updated

February 18, 2021

Results First Posted

February 11, 2019

Record last verified: 2018-09

Locations